List all clinical trials by discovery date. Accepts regular expressions in search.

GET /trials/?format=api&page=3
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 4794,
    "next": "http://api.gregory-ms.com/trials/?format=api&page=4",
    "previous": "http://api.gregory-ms.com/trials/?format=api&page=2",
    "results": [
        {
            "trial_id": 4292,
            "title": "The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis",
            "summary": null,
            "published_date": "2024-02-16T00:00:00Z",
            "discovery_date": "2024-03-13T11:01:28.548595Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06293079",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06293079"
            },
            "categories": [
                {
                    "category_id": 18,
                    "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs",
                    "category_name": "Physical therapy and Telerehabilitation",
                    "category_slug": "physical-therapy-and-telerehabilitation",
                    "category_terms": [
                        "telerehabilitation",
                        "physical therapy",
                        "virtual reality",
                        "gamification",
                        "neurostimulation",
                        "cognitive training",
                        "spasticity",
                        "motor control"
                    ],
                    "article_count": 174
                }
            ],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13797894",
            "last_refreshed_on": "2024-03-11",
            "scientific_title": "The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs on Gait, Functional Capacity, EMG Muscle Activation and Fatigue in Patients With Multiple Sclerosis",
            "primary_sponsor": "Biruni University",
            "retrospective_flag": "No",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "65 Years",
            "inclusion_gender": "All",
            "date_enrollement": "2023-08-30",
            "target_size": "45",
            "study_type": "Interventional",
            "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",
            "phase": "N/A",
            "countries": "Turkey",
            "contact_firstname": "; ;",
            "contact_lastname": "Guzin Kaya Aytutuldu;Güzin Kaya Aytutuldu;Güzin Kaya Aytutuldu",
            "contact_address": null,
            "contact_email": ";[email protected];[email protected]",
            "contact_tel": ";05366265884;05366265884",
            "contact_affiliation": "Biruni University;",
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          -  EDSS score of 0 - 4.0\r<br>\r<br>          -  Having high-speed internet access via smartphone or computer\r<br>\r<br>          -  Getting at least 24 points from the Mini Mental Test\r<br>\r<br>          -  Being at Stage 3 or above according to the Functional Ambulation Scale.\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  Having hearing or vision problems.\r<br>\r<br>          -  Participating in any exercise program.\r<br>\r<br>          -  Having other accompanying neurological, cardiovascular or orthopedic disorders\r<br>\r<br>          -  A history of MS attacks or a change in medication in the last 6 months.\r<br>\r<br>          -  Being in a physical condition that cannot do the exercises.\r<br>\r<br>          -  Comorbid conditions that negatively affect oxygen transport (severe anemia, peripheral\r<br>             artery diseases, etc.)\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Other: Exercise Program",
            "primary_outcome": "Gait Speed;Functional Capacity",
            "secondary_outcome": "EMG muscle activation;EMG muscle activation;Modified Fatigue Impact Scale",
            "secondary_id": "Researcher;BiruniUnive",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4291,
            "title": "The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis",
            "summary": null,
            "published_date": "2024-02-20T00:00:00Z",
            "discovery_date": "2024-03-13T11:01:28.491638Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06290453",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06290453"
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13797692",
            "last_refreshed_on": "2024-03-11",
            "scientific_title": "The Regulatory Role of miRNA 27 and Follistatin Like Protein-1 Gene in the Pathophysiology of Multiple Sclerosis Patients.",
            "primary_sponsor": "Assiut University",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Not recruiting",
            "other_records": "No",
            "inclusion_agemin": "20 Years",
            "inclusion_agemax": "45 Years",
            "inclusion_gender": "Female",
            "date_enrollement": "2024-03-27",
            "target_size": "60",
            "study_type": "Observational",
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": "",
            "contact_lastname": "Rasha Mohammed, Lecturer",
            "contact_address": null,
            "contact_email": "[email protected]",
            "contact_tel": "01010024021",
            "contact_affiliation": null,
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          1. Patients diagnosed with MS based on the revised McDonald criteria.\r<br>\r<br>          2. Female patients will only be included.\r<br>\r<br>          3. 20- 45 years old.\r<br>\r<br>          4. Drug naïve.\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  1. Patients with other neurodegenerative and autoimmune disorders. 2. Pregnant\r<br>             females. 3. Co-existing chronic hypertension, diabetes, and epilepsy 4. chronic renal\r<br>             or hepatic diseases\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Diagnostic Test: micro RNA 27- FLP1 gene expression;Diagnostic Test: The Expanded Disability Status Scale (EDSS);Diagnostic Test: Electrophysiological assessment:;Diagnostic Test: MRI examination MRI brain:",
            "primary_outcome": "• To measure the levels of miR-27 expression and its target gene (FSTL1) in progressive MS and relapsing-remitting multiple sclerosis (RRMS) patients.",
            "secondary_outcome": "To correlate the levels of expression of miR-27 expression and its target gene (FSTL1) relative to the severity of symptoms of MD patients.",
            "secondary_id": "AOGR",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4290,
            "title": "E-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity",
            "summary": null,
            "published_date": "2024-02-20T00:00:00Z",
            "discovery_date": "2024-03-13T11:01:28.469252Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06298201",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06298201"
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13798288",
            "last_refreshed_on": "2024-03-11",
            "scientific_title": "Investigating of Effects of e-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity",
            "primary_sponsor": "University of Southern Denmark",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "N/A",
            "inclusion_gender": "All",
            "date_enrollement": "2024-04-27",
            "target_size": "300",
            "study_type": "Interventional",
            "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",
            "phase": "N/A",
            "countries": "Denmark",
            "contact_firstname": "; ;",
            "contact_lastname": "Nasrin Asgari, Professor;Nasrin Asgari, Professor;Nasrin Asgari, Professor",
            "contact_address": null,
            "contact_email": ";[email protected];[email protected]",
            "contact_tel": ";+4530700612;+4530700612",
            "contact_affiliation": "Institute of Regional Health Research, University of Southern Denmark;",
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          1. Confirmed MS diagnosis as per the 2017 MS criteria. [3]\r<br>\r<br>          2. Expanded Disability Status Scale (EDSS) assessment score of less than 7.0 at baseline.\r<br>\r<br>          3. Adults aged 18 years or above.\r<br>\r<br>          4. Commitment and mental ability to participate in a 6-month e-based physical exercise\r<br>             program, supervised bi-weekly by a physiotherapist.\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>        5. Change in prophylactic DMT within the last 3 months 6. Steroid treatment in the past\r<br>        month. 7. Drug or alcohol abuse. 8. Pregnancy. 9. Active systemic infection\r<br>\r<br>        -\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Other: E-Based Physical Exercise Intervention",
            "primary_outcome": "6-meters' walk test;\"no evidence of disease activity\" (NEDA-3) score",
            "secondary_outcome": "Cognitive function, evaluated using the Montreal Cognitive Assessment (MoCA),;Fatigue levels, assessed using the short-form Neuro-QOL Fatigue Scale;Neurofilament Light Chain (NfL) determination",
            "secondary_id": "IMAGINE2024",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4289,
            "title": "Telerehabilitation Based Motor Imagery and Action Observation Training in Multiple Sclerosis",
            "summary": null,
            "published_date": "2024-02-21T00:00:00Z",
            "discovery_date": "2024-03-13T11:01:28.423236Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06295601",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06295601"
            },
            "categories": [
                {
                    "category_id": 18,
                    "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs",
                    "category_name": "Physical therapy and Telerehabilitation",
                    "category_slug": "physical-therapy-and-telerehabilitation",
                    "category_terms": [
                        "telerehabilitation",
                        "physical therapy",
                        "virtual reality",
                        "gamification",
                        "neurostimulation",
                        "cognitive training",
                        "spasticity",
                        "motor control"
                    ],
                    "article_count": 174
                }
            ],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13809179",
            "last_refreshed_on": "2024-03-18",
            "scientific_title": "Effect of Telerehabilitation-Based Motor Imagery and Action Observation Training on Balance and Functional Mobility in Multiple Sclerosis: Randomized Controlled Study",
            "primary_sponsor": "Inonu University",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Not recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "65 Years",
            "inclusion_gender": "All",
            "date_enrollement": "2024-03-20",
            "target_size": "10",
            "study_type": "Interventional",
            "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).",
            "phase": "N/A",
            "countries": null,
            "contact_firstname": ";",
            "contact_lastname": "Burcu talu;Busra CANDIRI",
            "contact_address": null,
            "contact_email": ";[email protected]",
            "contact_tel": ";+9005073780717",
            "contact_affiliation": "Inonu University;",
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          -  Being diagnosed with mulltiple sclerosis according to the McDonald criteria\r<br>\r<br>          -  Expanded Disability Status Scale<5.5,\r<br>\r<br>          -  Being between the ages of 18-65,\r<br>\r<br>          -  Mini mental test score>24,\r<br>\r<br>          -  Have a phone that can adapt to participating in a video call\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  Having another additional neurological disease that may cause balance and coordination\r<br>             disorders,\r<br>\r<br>          -  Receiving physical therapy in the last 6 months,\r<br>\r<br>          -  Having an attack in the last 3 months\r<br>\r<br>          -  Refusal to participate in the study.\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Other: Traditional rehabilitation;Other: Action observation therapy and motor imagery",
            "primary_outcome": "Berg Balance Scale;Berg Balance Scale;Muscle strength and functional mobility;Muscle strength and functional mobility",
            "secondary_outcome": "Fatigue Severity Scale;Fatigue Severity Scale;Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire;Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire",
            "secondary_id": "2024/5591",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4288,
            "title": "Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis.",
            "summary": null,
            "published_date": "2024-02-27T00:00:00Z",
            "discovery_date": "2024-03-13T11:01:28.335836Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06292312",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06292312"
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13797835",
            "last_refreshed_on": "2024-03-11",
            "scientific_title": "Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis: A Randomized Controlled, Single-Blind Study",
            "primary_sponsor": "Ankara Yildirim Beyazit University",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "65 Years",
            "inclusion_gender": "All",
            "date_enrollement": "2024-02-27",
            "target_size": "32",
            "study_type": "Interventional",
            "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).",
            "phase": "N/A",
            "countries": "Turkey",
            "contact_firstname": "; ;",
            "contact_lastname": "Hilal Aslan, MSc;Hilal Aslan, MSc;Hilal Aslan",
            "contact_address": null,
            "contact_email": ";[email protected];[email protected]",
            "contact_tel": ";05372565397;05372565397",
            "contact_affiliation": "Ankara Yildirim Beyazit University;",
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          -  18 to 65 years old\r<br>\r<br>          -  Definitive diagnosis of MS by a neurologist\r<br>\r<br>          -  EDSS score between 1-5.5\r<br>\r<br>          -  Not receiving active physical therapy services\r<br>\r<br>          -  Volunteering.\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  Having a neurological disease other than MS\r<br>\r<br>          -  Attacks in the last three months\r<br>\r<br>          -  Corticosteraoid use\r<br>\r<br>          -  History of surgery on the spine\r<br>\r<br>          -  Central and peripheral nervous system disease\r<br>\r<br>          -  Pregnancy\r<br>\r<br>          -  Oncological diseases\r<br>\r<br>          -  Severe comorbid somatic and psychiatric disorders\r<br>\r<br>          -  Receiving invasive/manipulative treatment.\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Other: Craniosacral therapy;Other: Conventional physiotherapy",
            "primary_outcome": "Dynamic posturography;Heart rate variability",
            "secondary_outcome": "Pain level;Central sensitization;Fatigue;Sleep quality;Life quality",
            "secondary_id": "19.12.2023/10-483",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4287,
            "title": "Étude multicentrique, randomisée en double aveugle versus placebo évaluant l’efficacité d’un traitement par Cholécalciférol (Vitamine D3) pour retarder la conversion en SEP après un syndrome cliniq...",
            "summary": "<p>EudraCT Number: 2013-000910-40<br />Sponsor Protocol Number: PHRC-N/2012/ET-01<br />Sponsor Name: CHU de Nîmes<br />Start Date: 2013-04-12<br />Medical condition: Les patients âgés de 18 à 50 ans ayant présenté depuis moins de 60 jours un SCI typique (NORB, myélite, syndrome du tronc cérébral ou sus-tentoriel) avec présence à l’IRM cérébro-médullaire de plus...<br />Disease: <br />Version: 18.0<br />SOC Term: 100000004852<br />Classification Code: 10028247<br />Term: Multiple sclerosis like syndrome<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000910-40/FR\">FR</a> (Completed)</p>",
            "published_date": null,
            "discovery_date": "2024-03-11T00:08:12.155663Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2013-000910-40",
            "source": "European Clinical Trials Register",
            "relevant": null,
            "identifiers": {
                "nct": null,
                "euct": "2013-000910-40",
                "eudract": "2013-000910-40"
            },
            "categories": [],
            "export_date": null,
            "internal_number": null,
            "last_refreshed_on": null,
            "scientific_title": null,
            "primary_sponsor": null,
            "retrospective_flag": null,
            "date_registration": null,
            "source_register": null,
            "recruitment_status": null,
            "other_records": null,
            "inclusion_agemin": null,
            "inclusion_agemax": null,
            "inclusion_gender": null,
            "date_enrollement": null,
            "target_size": null,
            "study_type": null,
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": null,
            "exclusion_criteria": null,
            "condition": null,
            "intervention": null,
            "primary_outcome": null,
            "secondary_outcome": null,
            "secondary_id": null,
            "source_support": null,
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4286,
            "title": "Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands",
            "summary": null,
            "published_date": "2023-02-20T00:00:00Z",
            "discovery_date": "2024-03-09T20:47:09.442940Z",
            "link": "https://onderzoekmetmensen.nl/en/trial/53285",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nl-omon": "NL-OMON53285"
            },
            "categories": [
                {
                    "category_id": 12,
                    "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies",
                    "category_name": "Stem Cells",
                    "category_slug": "stem-cells",
                    "category_terms": [
                        "stem cells",
                        "Autologous hematopoietic stem cell",
                        "ahsct"
                    ],
                    "article_count": 221
                },
                {
                    "category_id": 40,
                    "category_description": "Autologous hematopoietic stem cell transplantation\n\nSearch terms: ahsct,Autologous hematopoietic stem cell transplantation,Bone marrow,Mesenchymal stem cells,Immunoablation",
                    "category_name": "aHSCT",
                    "category_slug": "ahsct",
                    "category_terms": [
                        "ahsct",
                        "Autologous hematopoietic stem cell transplantation",
                        "Bone marrow",
                        "Immunoablation"
                    ],
                    "article_count": 90
                }
            ],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13758630",
            "last_refreshed_on": "2024-03-04",
            "scientific_title": "Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands\n - MS-ACT",
            "primary_sponsor": "Vrije Universiteit Medisch Centrum",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "NL-OMON",
            "recruitment_status": "Not Recruiting",
            "other_records": "No",
            "inclusion_agemin": "18",
            "inclusion_agemax": "64",
            "inclusion_gender": null,
            "date_enrollement": "2023-09-01",
            "target_size": "24",
            "study_type": "Observational invasive",
            "study_design": "Open (masking not used), Uncontrolled, Treatment",
            "phase": "4",
            "countries": "Netherlands",
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": "De Boelelaan 1118",
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": "Vrije Universiteit Medisch Centrum",
            "inclusion_criteria": "Inclusion criteria: <p>All patients who undergo aHSCT for the treatment of RRMS in the Netherlands are <br>eligible to participate in this observational study.</p>\r<br>",
            "exclusion_criteria": "Exclusion criteria: <p>The only exclusion criteria for this observational study is unwillingness to <br>participate or to sign informed consent.</p>\r<br>",
            "condition": "<br>MS <br>Multiple sclerosis;10003816;10012303",
            "intervention": "<p></p><br>",
            "primary_outcome": "<p>Patients will be subjected to frequent visits with clinical, radiological and<br /><br>biomarker follow-up until five years after aHSCT (primary phase and extension<br /><br>phase). During these visits, clinical testing, evaluation by questionnaires,<br /><br>MRI scans and blood sampling will be performed.<br /><br><br /><br>The main study parameters are: 1. no evidence of disease activity (meaning no<br /><br>MS relapses, no disability progression and no MS MRI activity, i.e. NEDA3)</p><br>",
            "secondary_outcome": "<p>Secundary study parameters are safety and tolerability of aHSCT, biomarkers and<br />\r<br>longitudinal analysis of immune reconstitution.</p>\r<br>",
            "secondary_id": "NL83783.018.23",
            "source_support": "Stichting Annie van Coeverden",
            "ethics_review_status": "Approved",
            "ethics_review_approval_date": "2023-08-25",
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4285,
            "title": "The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients:",
            "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Sponsors</b>: Assiut University\n<br /><b>Not yet recruiting</b>",
            "published_date": "2024-09-01T00:00:00Z",
            "discovery_date": "2024-03-09T20:47:05.508190Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06280131",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06280131",
                "euct": null,
                "eudract": null
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13756669",
            "last_refreshed_on": "2024-03-04",
            "scientific_title": "The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients: Clinical and Neurophysiology Study.",
            "primary_sponsor": "Assiut University",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Not recruiting",
            "other_records": "No",
            "inclusion_agemin": "N/A",
            "inclusion_agemax": "N/A",
            "inclusion_gender": "All",
            "date_enrollement": "2024-03-01",
            "target_size": "30",
            "study_type": "Observational [Patient Registry]",
            "study_design": null,
            "phase": null,
            "countries": null,
            "contact_firstname": "",
            "contact_lastname": "Entsar karem, resident",
            "contact_address": null,
            "contact_email": "[email protected]",
            "contact_tel": "0201030698902",
            "contact_affiliation": null,
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          -  Any adult patient's clinical history and neuroimaging fulfilling revised McDonald\r<br>             diagnostic criteria of Multiple sclerosis in an acute relapsing episode or attack and\r<br>             could be providing consent for participation in the study, will be included in the\r<br>             study.\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  -Any patient had an infection or febrile condition.\r<br>\r<br>          -  Any patient had other co-morbid neurological or psychiatric disorders or systemic\r<br>             disease or had contraindications for receiving pulse therapy (high steroid dose) or\r<br>             showed side effects of steroids or intolerance or seizure.\r<br>\r<br>          -  Any patient refuses participation in the study.\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": null,
            "primary_outcome": "to evaluate efficacy of a pulse therapy on clinical outcome",
            "secondary_outcome": "clinical correlation between clinical scales scores and neurophysiological changes(visual evoked potional;clinical correlation between clinical scales scores and neurophysiological changes( cortical exitability parameters)",
            "secondary_id": "multiple sclerosis and pulse",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4284,
            "title": "A French Network for PET Imaging of Neuroinflammation in MS (INFLANET)",
            "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Radiation: PET-MRI with [18F]-DPA-714\n<br /><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris\n<br /><b>Not yet recruiting</b>",
            "published_date": "2024-01-23T00:00:00Z",
            "discovery_date": "2024-03-09T20:47:05.360242Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06280742",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06280742",
                "euct": null,
                "eudract": null
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13756716",
            "last_refreshed_on": "2024-03-04",
            "scientific_title": "A French Network for PET Imaging of Neuroinflammation in MS",
            "primary_sponsor": "Assistance Publique - Hôpitaux de Paris",
            "retrospective_flag": "Yes",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Not recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "N/A",
            "inclusion_gender": "All",
            "date_enrollement": "2024-07-01",
            "target_size": "41",
            "study_type": "Interventional",
            "study_design": "Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).",
            "phase": "N/A",
            "countries": "France",
            "contact_firstname": "",
            "contact_lastname": "Bruno Stankoff, MD",
            "contact_address": null,
            "contact_email": "[email protected]",
            "contact_tel": "0171970659",
            "contact_affiliation": null,
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>        RRMS patients:\r<br>\r<br>          -  Age between 18 and 55 years old\r<br>\r<br>          -  RRMS according to the 2017 Mc Donald criteria\r<br>\r<br>          -  At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI\r<br>\r<br>          -  Last treatment with methylprednisolone should have been performed at least 1 month\r<br>             before PET examinations\r<br>\r<br>          -  No current disease modifying therapy\r<br>\r<br>          -  Indication for a highly active disease modifying treatment: Natalizumab, anti CD20\r<br>             antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will\r<br>             consist either as patients with an active form of relapsing MS or patients who have\r<br>             experienced two relapses during the previous year\r<br>\r<br>          -  Affiliation to a social security scheme or beneficiary of such a scheme (except \"Aide\r<br>             Médicale d'Etat\")\r<br>\r<br>        Healthy Volunteers:\r<br>\r<br>          -  Age between 18 and 55 years old\r<br>\r<br>          -  Without any evolutive pathology\r<br>\r<br>          -  Able to understand the study objectives and procedures\r<br>\r<br>          -  Affiliation to a social security scheme or beneficiary of such a scheme (except \"Aide\r<br>             Me´dicale d'Etat\")\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>        For all participants:\r<br>\r<br>          -  Any reasons, which does not allow to perform MRI, including claustrophobia, the\r<br>             implant of a pace-maker or the presence of an intra-ocular foreign body, (a\r<br>             contra-indication questionnaire will be filled in beforehand)\r<br>\r<br>          -  PET for clinical research already done within the last 12 months\r<br>\r<br>          -  Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit)\r<br>\r<br>          -  Pregnancy, breast-feeding, lack of efficient contraception for women of childbearing\r<br>             potential\r<br>\r<br>          -  Current symptoms of severe or uncontrolled renal, hepatic, hematological,\r<br>             gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological\r<br>             diseases\r<br>\r<br>          -  Unwillingness to be informed in case of unexpected MRI abnormality (with a significant\r<br>             medical anomaly)\r<br>\r<br>          -  Patient under legal protection\r<br>\r<br>          -  Participation in another interventional study or being in the exclusion period at the\r<br>             end of a previous study\r<br>\r<br>        RRMS patients:\r<br>\r<br>          -  Hypersensitivity to gadoteric acid\r<br>\r<br>          -  Meglumine or any drug containing gadolinium\r<br>\r<br>          -  Severe renal insufficiency (creatinine clearance < 60mL/min and GFR <30ml / min /\r<br>             1.73m2).\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Radiation: PET-MRI with [18F]-DPA-714",
            "primary_outcome": "To quantify the smoldering component of white matter lesions in people with MS, as compared with [18F]-DPA-714 binding in the white matter of HC who underwent a PET a acquisition with the same camera camera than patients in each center.",
            "secondary_outcome": "To quantify for each patient the regional neuroinflammatory load, measured as [18F]-DPA-714 DVR, in specific regions of interest: total brain, normal appearing white matter, cortex, thalami, deep grey matter.;The MRI signatures of each lesional subtypes, and correlation between MRI metrics and [18F]-DPA-714 DVR in each region of interest.",
            "secondary_id": "APHP221366",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        },
        {
            "trial_id": 4283,
            "title": "COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS)",
            "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Combination Product: Wim Hoff method\n<br /><b>Sponsors</b>: Comenius University\n<br /><b>Active, not recruiting</b>",
            "published_date": "2024-01-23T00:00:00Z",
            "discovery_date": "2024-03-09T20:47:05.340315Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT06280573",
            "source": "WHO XML import",
            "relevant": null,
            "identifiers": {
                "nct": "NCT06280573",
                "euct": null,
                "eudract": null
            },
            "categories": [],
            "export_date": "2024-03-27T00:00:00Z",
            "internal_number": "13797305",
            "last_refreshed_on": "2024-03-11",
            "scientific_title": "COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS)",
            "primary_sponsor": "Comenius University",
            "retrospective_flag": "No",
            "date_registration": null,
            "source_register": "ClinicalTrials.gov",
            "recruitment_status": "Not recruiting",
            "other_records": "No",
            "inclusion_agemin": "18 Years",
            "inclusion_agemax": "55 Years",
            "inclusion_gender": "All",
            "date_enrollement": "2022-09-01",
            "target_size": "50",
            "study_type": "Interventional",
            "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).",
            "phase": "N/A",
            "countries": "Slovakia",
            "contact_firstname": null,
            "contact_lastname": null,
            "contact_address": null,
            "contact_email": null,
            "contact_tel": null,
            "contact_affiliation": null,
            "inclusion_criteria": "<br>        Inclusion Criteria:\r<br>\r<br>          -  RRMS diagnosed according to the official 2020 McDonald's criteria,\r<br>\r<br>          -  age 18-55 years,\r<br>\r<br>          -  MS duration up to 10 years,\r<br>\r<br>          -  EDSS 1.0-5.5,\r<br>\r<br>          -  willingness to participate\r<br>\r<br>        Exclusion Criteria:\r<br>\r<br>          -  relapse or corticosteroid treatment within 3 months prior to study enrollment\r<br>\r<br>          -  severe/unstable comorbidity\r<br>",
            "exclusion_criteria": null,
            "condition": "Multiple Sclerosis",
            "intervention": "Combination Product: Wim Hoff method",
            "primary_outcome": "concentration of pro-inflammatory cytokines;concentration of markers of oxidative stress;concentration of NfL;concentration of GFAP;concentration of ecDNA",
            "secondary_outcome": "Expanded Disability Status Scale;Timed 25-Foot Walk;Nine-Hole Peg Test;Symbol Digit Modalities Test;Fatigue Scale for Motor and Cognitive Functions;General Anxiety Disorder-7;Patient Health Questionnaire-9",
            "secondary_id": "MS1",
            "source_support": "Please refer to primary and secondary sponsors",
            "ethics_review_status": null,
            "ethics_review_approval_date": null,
            "ethics_review_contact_name": null,
            "ethics_review_contact_address": null,
            "ethics_review_contact_phone": null,
            "ethics_review_contact_email": null,
            "results_date_completed": null,
            "results_url_link": null
        }
    ]
}